Jillian Lloyd, MD, MPH, FACS
An interdisciplinary approach to reducing health disparities for low income Appalachian women with estrogen-positive breast cancer
There are substantial health disparities in the Appalachian region especially for patients with breast cancer, who have a 15% higher chance of dying from the disease compared to the rest of the country.
This study aims to reduce health disparities in Appalachia using a biopsychosocial approach to identify the association between the patient/caregiver relationship qualities (support and strain) and mutable factors (e.g. physiological and psychological distress).
The goal of the study is to elucidate the biopsychosocial pathways to enable improved estrogen-positive breast cancer treatment and reduce health disparities among patients with estrogen positive breast cancer.
Collaborator: University of Tennessee College of Nursing, Knoxville TN Research Team: Patricia Roberson, Ph.D.
Larry Kilgore, MD, FACOG, FACS
Developing a coordinated model to increase HPV vaccine education, recommendations and uptake
The number of human papillomavirus-related cancer cases has dramatically increased by nearly 45 percent over the past 15 years.
The human papillomavirus (HPV) vaccine is the only vaccine available to prevent cancer and it is highly effective, yet vaccination coverage is below Healthy People 2020 goals. The fields of dentistry and pharmacy can play an important role in developing a more coordinated model of care to increase HPV vaccination coverage and decrease HPV related cancers.
The proposed study will assess dental health provider knowledge of HPV and confidence in discussing the HPV vaccine pre and post-educational intervention in East Tennessee and determine accessibility of the HPV vaccination among regional pharmacies using novel methodologies.
Research Team: Nikki Zite, MD, Jill Maples, Ph.D., Samantha Gregory, Megan Lacy, Tyler Davis, DDS
Laurentia Nodit, MD
Oral microbiome changes in cancer therapy-induced oral mucositis: a pilot study
Cancer therapy-induced oral mucositis (CTOM) is a frequent and devastating side-effect secondary to cancer treatment, estimated to occur in approximately 40% of patients undergoing chemotherapy and almost 100% of those treated by chemo-radiation therapy for head and neck cancers. It can cause significant pain, eating difficulty and increased use of total parenteral nutrition, infection risk and opioid use.
Using healthy volunteers and patients with oral cancer at the time of diagnosis, as well as during and after chemo-radiation treatment, this study will evaluate oral bacterial composition before, during and after therapy.
Understanding microbiome changes may provide promising new directions toward novel diagnostic tools, biomarkers and therapeutic interventions for CTOM.
Collaborator: Oak Ridge National Laboratory, Oak Ridge, TN.
Research Team:Joseph Kelley, MD, Ante Bruckbauer, Ph.D., Timothy Panella, MD and Mircea Podar, Ph.D.